Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, child: Other
Stage/Subtype:  recurrent childhood brain tumor
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 54 for your search:
Start Over
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-03173, CDR667932, PBTC-029B, PBTC-029, U01CA081457, UM1CA081457, NCT01089101
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: Re-MATCH, W81XWH-10-1-0089, CDMRP-PRO93877, NCT01326104
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: 2011-0804, NCI-2011-03725, NCT01469247
Aerosol IL-2 for Pulmonary Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCI-2012-00788, NCT01590069
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: Other
Protocol IDs: 2011-0844, NCI-2012-00849, NCT01596127
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: 1202012214, NCT01884740
WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2014-00547, ADVL1312, UM1CA097452, NCT02095132
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: V0706, NCT00601003
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066504, BC-BT-13, NCT00003468
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066514, BC-BT-23, NCT00003477
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: Poly ICLC, 004385, NCT01188096
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2011-02605, CDR0000686608, COG-ACNS0821, ACNS0821, U10CA180886, U10CA098543, NCT01217437
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 3 to 21
Sponsor: Other
Protocol IDs: CC#120817, NCT01734512
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 18
Sponsor: Other
Protocol IDs: NMTRCPG007, NCT01774253
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: RERTEP, NCI-2014-00906, NCT02125786
Start Over